TOG Review (RCOG Journal)

MRCOG Part 2

Gynaecological Problems

Endometrial pathology in the postmenopausal woman – an evidence based approach to management

Key Statistics

  • 60–80% — PMB due to atrophic endometritis/vaginitis
  • 5 mm — Standard TVUS abnormal endometrial cut-off
  • 2.3% — Malignancy risk, polyp + PMB

Don't-miss facts

  1. PMB causes: atrophic endometritis/vaginitis 60–80% · exogenous estrogen 15–25% · carcinoma 10% · hyperplasia 5– 10% · polyps 2–12%

  2. Asymptomatic polyp malignancy risk 0.3%; abnormal histology odds ×6.9 if diameter >18 mm – symptomatic polyps always removed, asymptomatic weighed individually

  3. Untreated hyperplasia progression: no atypia 2% · atypical 23% · complex atypical 29%

  4. LNG-IUS > oral MPA for endometrial regression in complex/atypical hyperplasia (100% vs 96% continuous / 69% cyclical at 6 months)

  5. Tamoxifen ↑endometrial thickness 0.75 mm/year; pipelle EMB unreliable – use hysteroscopy + targeted biopsy if symptomatic

  6. HRT: investigate only if symptomatic AND thickness >8 mm; PEPI – 5 mm cut-off in asymptomatic users would over- biopsy (>50% for 4% disease)

  7. Routine screening of ANY asymptomatic postmenopausal group (general, HRT, tamoxifen) is not recommended – not evidence-based/cost-effective

  8. Standard abnormal TVUS threshold = 5 mm; if thickness not visualised in a symptomatic woman → proceed to hysteroscopy (higher cancer odds)

Diagnostic accuracy at a glance

Hysteroscopy+biopsy: sens 100%, spec 97% TVUS: sens 97%, spec 74% (vs hysteroscopic biopsy)

TVS asymptomatic screening: 93.2% false positive

Abbreviation Key

  • PMB — postmenopausal bleeding
  • LNG-IUS — levonorgestrel-releasing intrauterine system
  • TVUS/TVS — transvaginal ultrasound/scan
  • MPA — medroxyprogesterone acetate
  • SIS — saline infusion sonography
  • GnRH — gonadotropin-releasing hormone
  • GIS — gel instillation sonography
  • PPV/NPV — positive/negative predictive value
  • EMB — endometrial biopsy
  • PEPI — Postmenopausal Estrogen/Progestogen Interventions trial
  • HRT — hormone replacement therapy
  • MORE — Multiple Outcomes of Raloxifene Evaluation trial
  • SERM — selective estrogen receptor modulator

Source: Otify M et al. Endometrial pathology in the postmenopausal woman – an evidence based approach to management. The Obstetrician & Gynaecologist 2015;17:29–38. doi:10.1111/tog.12150

MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).

Included with a Pass Package

  • Audio overview of this guideline
  • Practice questions drawn from it
  • AI tutor answers grounded in its text
  • Your own annotations
Start free